

Haakon E. Meyer, MD, PhD; Walter C. Willett, MD, DrPH; Teresa T. Fung, ScD, RD; Kristin Holvik, PhD; Diane Feskanich, ScD

# Abstract

**IMPORTANCE** Vitamin supplementation far exceeding recommended doses is popular in segments of the population. However, adverse effects can occur. In a previous secondary analysis of combined data from 2 double-blind randomized clinical trials (RCTs), an unexpected increased risk of hip fracture was found among those treated with high doses of vitamin B<sub>6</sub> in combination with vitamin B<sub>12</sub>.

**OBJECTIVES** To study if high intakes of vitamins  $B_6$  and  $B_{12}$  from food and supplements were associated with a risk of hip fracture in the Nurses' Health Study and to investigate whether combined high intakes of both vitamins conferred a particularly increased fracture risk.

**DESIGN, SETTING, AND PARTICIPANTS** In this prospective cohort study, 75 864 postmenopausal women in the United States were followed up from June 1984 through May 2014. The dates of analysis were July 2016 to June 2018. Information on hip fracture and a wide range of potential confounders was collected at baseline and with biennial follow-up questionnaires. Extensive dietary information was collected approximately every 4 years with a semiquantitative food frequency questionnaire. Relative risks (RRs) were calculated by Cox proportional hazards regression, with cumulative average intakes of vitamins B<sub>6</sub> and B<sub>12</sub> as main exposures, adjusting for potential confounders.

MAIN OUTCOME AND MEASURE Hip fracture.

**RESULTS** During follow-up, 2304 of 75 864 women had a hip fracture. Among the women with hip fractures, the median (range) age at hip fracture was 75.8 (46.7-93.0) years and the mean (SD) body mass index (calculated as weight in kilograms divided by height in meters squared) was 24.3 (4.6). Median (interquartile range) cumulative average intakes of total vitamins B<sub>6</sub> and B<sub>12</sub> were 3.6 (4.8) mg/d and 12.1 (11.7) µg/d, respectively. Both vitamin B<sub>6</sub> (RR, 1.29; 95% CI, 1.04-1.59 for an intake of  $\geq$ 35 vs <2 mg/d; *P* = .06 for linear trend) and vitamin B<sub>12</sub> (RR, 1.25; 95% CI, 0.98-1.58 for an intake of  $\geq$ 30 vs <5 µg/d; *P* = .02 for linear trend) were associated with increased fracture risk. Risk was highest in women with a combined high intake of both vitamins (B<sub>6</sub>  $\geq$ 35 mg/d and B<sub>12</sub>  $\geq$ 20 µg/d), exhibiting an almost 50% increased risk of hip fracture (RR, 1.47; 95% CI, 1.15-1.89) compared with women with a low intake of both vitamins (B<sub>6</sub> <2 mg/d and B<sub>12</sub> <10 µg/d).

**CONCLUSIONS AND RELEVANCE** In this cohort study, a combined high intake of vitamins  $B_6$  and  $B_{12}$  was associated with an increased risk of hip fracture. The intakes were far higher than the recommended dietary allowances. These findings add to previous studies suggesting that vitamin supplements should be used cautiously because adverse effects can occur.

JAMA Network Open. 2019;2(5):e193591. doi:10.1001/jamanetworkopen.2019.3591

Den Access. This is an open access article distributed under the terms of the CC-BY License.

JAMA Network Open. 2019;2(5):e193591. doi:10.1001/jamanetworkopen.2019.3591

**Question** Are high intakes of vitamins B<sub>6</sub> and B<sub>12</sub> associated with an increased risk of hip fracture?

**Findings** In a cohort study of 75 864 US postmenopausal women, 2304 had a hip fracture. A combined high intake of vitamins  $B_6$  and  $B_{12}$  was associated with an increased risk of hip fracture.

Meaning These results add to the evidence suggesting that caution should be used in vitamin supplementation when there is no apparent deficiency.

### Supplemental content

Author affiliations and article information are listed at the end of this article.

# Introduction

Vitamin supplementation is widely popular. In the National Health and Nutrition Examination Survey (NHANES), approximately 50% of US adults reported taking at least 1 dietary supplement.<sup>1</sup> The prevalence of use increased by age and was highest among individuals of non-Hispanic white race/ ethnicity and among those with the highest education. Among US nurses, 28% reported using at least 4 dietary supplements.<sup>2</sup>

Both insufficient and excess intakes of a nutrient may be harmful. According to randomized clinical trials (RCTs), high-dose vitamin supplementation may lead to unexpected adverse effects.<sup>3-6</sup> Based on the concept that high homocysteine concentrations could cause disease, several large RCTs have been performed. However, they failed to demonstrate a preventive effect of vitamin B supplementation on cardiovascular diseases and cancer,<sup>7-10</sup> and possible adverse effects have been reported.<sup>9,11,12</sup> Although hyperhomocysteinemia also may negatively influence bone quality by disturbing collagen cross-linkage and stimulating bone resorption,<sup>13</sup> high doses of vitamin B<sub>12</sub> and folic acid supplementation have not shown a fracture-preventing effect in RCTs.<sup>14</sup> In a previous secondary analysis of combined data from 2 double-blind RCTs with factorial design,<sup>15</sup> an unexpected increased risk of hip fracture was found among those treated with high doses of vitamin B<sub>6</sub>. The highest fracture risk was seen in the trial arm combining vitamin B<sub>6</sub> and vitamin B<sub>12</sub>.

It is unlikely that new large trials of vitamin  $B_6$  and vitamin  $B_{12}$  will be carried out in the future. We aimed to study if high intakes of vitamins  $B_6$  and  $B_{12}$  from food and supplements were associated with a risk of hip fracture in the Nurses' Health Study (NHS) and to investigate whether combined high intakes of both vitamins were associated with a particularly increased fracture risk.

# Methods

# **Study Population**

The NHS was initiated in 1976 among 121 701 female registered nurses in the United States aged 30 to 55 years. They responded to a mailed questionnaire concerning medical history, lifestyle, and disease risk factors. Every 2 years, follow-up questionnaires have been mailed to update individual characteristics and to identify incident diagnoses. Postmenopausal women entered the present analysis in 1984, when vitamin B supplement use was first assessed; otherwise, they entered the questionnaire cycle when they reached menopause. As shown in the flowchart in the eFigure in the Supplement, the final study sample included 75 864 postmenopausal women for our primary analysis. The women were followed up from June 1984 through May 2014. The dates of analysis were July 2016 to June 2018. The follow-up rate for this study population was 92% over the period of our analysis.

Completion and return of the self-administered questionnaires constituted informed consent. The investigation was approved by the Institutional Review Board at Brigham and Women's Hospital, Boston, Massachusetts. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for cohort studies.

# **Hip Fractures**

On every biennial follow-up questionnaire, information about hip fracture (with the date of occurrence and a description of the circumstances) was requested. As nurses, they were expected to be capable of reporting hip fractures, as demonstrated in a small validation study<sup>16</sup> in which all 30 self-reports were confirmed by medical records. Hip fractures were also identified from death records. For the primary cumulative average analysis, hip fractures were recorded in 2304 of 75 864 women during follow-up after exclusion of 117 fractures due to cancer or major traumatic events.

#### **Diet and Vitamin Supplement Use**

Diet was assessed with a semiquantitative food frequency questionnaire (FFQ) in 1984, 1986, and every 4 years thereafter until 2010. Participants reported their habitual frequency of consumption over the previous year for specified serving sizes of more than 130 foods. Daily energy and nutrient intakes were calculated from the total diet.

The FFQ requested information on current use of supplements, such as vitamin  $B_6$ , folic acid, vitamin B complex, vitamin  $B_{12}$ -only supplements (beginning in 1998), multivitamins, vitamin A, vitamin D, and calcium. For vitamin  $B_6$  and vitamin A, information on daily dose was requested. For multivitamins, the respondents were asked to report the brand name and number of pills per week. Information on frequency and dose for other supplements was not obtained.

Vitamin intakes (except those from supplements only) were adjusted for total energy intake using regression analysis.<sup>17</sup> In a validation study<sup>18</sup> among 632 women in the NHS and the younger NHS2 cohort, correlations between intakes from the FFQ and 7-day diet records were 0.68 for total vitamin B<sub>6</sub> and 0.68 for total vitamin B<sub>12</sub>. A correlation of 0.52 between total vitamin B<sub>6</sub> in the food and plasma vitamin B<sub>6</sub> (pyridoxal 5'-phosphate) and a corresponding correlation of 0.25 for vitamin B<sub>12</sub> have been reported in another substudy within the NHS.<sup>19</sup>

### **Nondietary Measures**

On all biennial follow-up questionnaires, the following measures were assessed: weight; hours per week spent in recreational activities; smoking status; menopausal status and use of postmenopausal hormone therapy; diagnoses of cancer, diabetes, cardiovascular disease, and osteoporosis; and use of thiazide diuretics, furosemide-like diuretics, and oral corticosteroids. We calculated total metabolic energy expenditure (metabolic equivalent [MET] hours per week) from the reported recreational activities<sup>20</sup> and body mass index (BMI) (calculated as weight in kilograms divided by height in meters squared) from current weight and height on the initial cohort questionnaire.

Questions concerning difficulties with balance, climbing a flight of stairs, or walking 1 block were included on questionnaires beginning in 1992, and questions on falls and pernicious anemia were included from 1998 onward. Self-rated general health status was requested in 1992, 1996, and 2000.

# **Statistical Analysis**

Participants were followed up to the date of first self-reported hip fracture or death from hip fracture, last questionnaire response, or the end of follow-up in 2014. In our primary analyses, we used vitamin  $B_6$ , vitamin  $B_{12}$ , and other nutrient intakes that were cumulatively averaged over follow-up. At the beginning of each new FFQ cycle, the intakes were updated with the mean of all assessments up to that time. Intakes were carried forward 1 cycle to replace missing data, and we excluded person-time in cycles in which women failed to report their dietary intake on the 2 most recent FFQs.

In alternate analyses, we used current intakes of vitamins and other nutrients (calculated as the mean of the 2 most recent FFQs) among 96 467 women with 2812 hip fractures (eFigure in the Supplement). Participants who had the 2 most recent dietary assessments missing for a cycle did not contribute person-time in that cycle.

Cross-sectional age-adjusted characteristics in the 2002 questionnaire cycle by categories of total vitamin  $B_6$  and  $B_{12}$  were recorded. We used Cox proportional hazards regression to compute hazard ratios (hereafter referred to as relative risks [RRs]) of hip fracture with 95% CIs according to predefined categories of vitamins  $B_6$  and  $B_{12}$ . Cumulative average intakes of vitamins  $B_6$  and  $B_{12}$  were the main exposures. Separate analyses were performed for total vitamin intakes (from diet plus supplements) and intakes from supplements only. For vitamin  $B_6$ , the 5 categories of total intakes ranged from less than 2 mg/d to at least 35 mg/d, and the 5 categories of intakes from supplements only ranged from 0 mg/d (no supplement use) to at least 25 mg/d. For vitamin  $B_{12}$ , the 5 categories of total intakes from supplements only ranged from less than 5 µg/d to at least 30 µg/d, and the 5 categories of intakes from supplements only ranged from 0 µg/d (no supplement use) to at least 25 µg/d. We also ran models with continuous intakes to test for linear trend. Based on the results from the previous RCT<sup>15</sup> and

from the categories used for vitamins  $B_6$  and  $B_{12}$ , combined categories of vitamins  $B_6$  and  $B_{12}$  intakes were created.

All Cox proportional hazards regression models were stratified by age and questionnaire cycle to account for age and time. Relative risks were calculated from models using time-varying exposure and covariates (ie, person-time was assigned to the appropriate category for each variable at the beginning of every biennial follow-up questionnaire cycle). Multivariable RRs were computed from models that adjusted for potential dietary and nondietary confounding factors. For categorical covariates, missing data were assigned as a separate category. Less than 2% of the observations had missing data for BMI, physical activity, and smoking, and 5% of the observations had missing data for postmenopausal hormone therapy.

Multiplicative interactions between exposures were calculated using the Wald test for continuous data. The proportional hazards assumption was tested by including interaction terms between age and vitamin  $B_6$  and vitamin  $B_{12}$ , respectively. In exploratory analyses, we also examined if the associations between vitamin  $B_6$  and vitamin  $B_{12}$  and risk of hip fracture differed by BMI and physical activity.

Data were analyzed using statistical software (SAS, version 9.4; SAS Institute Inc). Two-sided statistical tests were used, and P < .05 indicated statistical significance.

# Results

Among the 2304 fracture cases, the median age at hip fracture was 75.8 years (age range, 46.7-93.0 years). These women had a mean (SD) BMI of 24.3 (4.6), and median (IQR) cumulative average intakes of total vitamins  $B_6$  and  $B_{12}$  were 3.6 (4.8) mg/d and 12.1 (11.7) µg/d, respectively.

Height and BMI differed little across cumulative average intake categories of vitamin  $B_6$ (**Table 1**) and  $B_{12}$  (**Table 2**) in 2002, the approximate midpoint in follow-up, whereas physical activity increased and smoking prevalence decreased with higher intakes of both vitamins. Intakes of other micronutrients were also higher by increasing intakes of vitamins  $B_6$  and  $B_{12}$ , whereas caffeine and alcohol consumption decreased. The reported prevalences of functional limitations, chronic diseases, and medication use tended to be lowest at low vitamin  $B_{12}$  intakes but were similar at middle and high intakes. Although less apparent, a similar pattern was found for vitamin  $B_6$ . The Pearson product moment correlation coefficient between total intake of vitamins  $B_6$  and  $B_{12}$  was r = 0.51 (P < .001). Correlation coefficients between total vitamin  $B_6$  intake and the other vitamins were 0.35 for folate (P < .001), 0.28 for vitamin D (P < .001), and 0.37 for retinol (P < .001), 0.33 for vitamin D (P < .001).

The mean follow-up time was 20.9 years (1586 155 person-years of follow-up). Compared with the reference category of total vitamin B<sub>6</sub> less than 2 mg/d, an intake at least 35 mg/d was associated with an increased risk of hip fracture after adjusting for all covariates (RR, 1.29; 95% CI, 1.04-1.59; P = .06 for linear trend) (**Table 3**). For vitamin  $B_6$  from supplements only, those consuming no vitamin B<sub>6</sub> supplements had the lowest risk compared with a similar increased risk in the other groups. For total vitamin  $B_{12}$ , intakes at least 30  $\mu$ g/d were associated with a nonsignificant increased risk of hip fracture compared with intakes less than 5 µg/d (RR, 1.25; 95% CI, 0.98-1.58), and risk increased linearly with increasing intake (RR, 1.01; 95% CI, 1.00-1.03 per 10-µg/d increase in total intake; P for linear trend = .02). Similar results were found for vitamin  $B_{12}$  intakes from supplements only (Table 3). The interaction term for the 2 vitamins on fracture risk was not significant. In analyses that included mutual adjustment for total B<sub>6</sub> and B<sub>12</sub> intakes, the associations were somewhat attenuated, with an RR of 1.19 (95% CI, 0.95-1.49) for vitamin B<sub>6</sub> at least 35 mg/d vs less than 2 mg/d and an RR of 1.22 (95% CI, 0.94-1.57) for vitamin  $B_{12}$  at least 30 µg/d vs less than 5 µg/d. In fully adjusted models that included adjustment for intake from supplements, there was no clear association between vitamin B<sub>6</sub> from diet only and hip fracture (RR, 1.03; 95% CI, 0.91-1.16 per 1-mg/d increase in intake from food only; P for linear trend = .67) or between vitamin  $B_{12}$  from diet only and

hip fracture (RR, 1.01; 95% CI, 0.99-1.02 per  $1-\mu g/d$  increase in intake from food only; *P* for linear trend = .54).

Women with a high intake of both vitamins had a significantly increased risk of hip fracture compared with the reference category of a low intake of both vitamins (RR, 1.47; 95% CI, 1.15-1.89) (**Table 4**). Among women in the medium-intake categories for both vitamins, risk was not significantly elevated (RR, 1.18; 95% CI, 0.98-1.42). Few women had low intakes of one vitamin and high intakes of the other.

There was a significant interaction between total vitamin  $B_6$  intake and BMI on hip fracture risk, while the interaction between total vitamin  $B_{12}$  intake and BMI was not significant. The results for total vitamins  $B_6$  and  $B_{12}$  intakes stratified by BMI are summarized in **Table 5**. The associations between vitamin  $B_6$  and vitamin  $B_{12}$  and hip fracture were stronger in women with BMI less than 25 compared with the overall analyses, whereas there were no clear associations in women with BMI at least 25. Among women with BMI less than 25, those with a high intake of both vitamins  $B_6$  and  $B_{12}$ 

Table 1. Age and Age-Adjusted Characteristics of 61 445 Women in the Nurses' Health Study Across Categories of Total Vitamin B<sub>6</sub> Intake (Diet and Supplements) in 2002, Cumulative Mean<sup>a</sup>

|   | Vitamin B <sub>6</sub> Intake, mg/d |               |             |            |           |  |
|---|-------------------------------------|---------------|-------------|------------|-----------|--|
| Variable  | <2                                  | 2-4.9         | 5-14.9      | 15-34.9    | ≥35       |  |
| No. (%) of population <sup>b</sup>                | 8416 (13.7)                         | 33 660 (54.8) | 8022 (13.1) | 5965 (9.7) | 5382 (8.8 |  |
| Age, mean, y                                      | 67.2                                | 68.1          | 68.8        | 68.3       | 66.5      |  |
| Height at baseline, mean, cm                      | 164                                 | 164           | 164         | 164        | 164       |  |
| Current BMI, mean                                 | 26.8                                | 26.7          | 26.6        | 26.5       | 26.3      |  |
| Physical activity, MET, mean, h/wk <sup>c</sup>   | 13.8                                | 17.4          | 18.7        | 18.8       | 19.3      |  |
| Current smoker, %                                 | 13.9                                | 7.0           | 6.3         | 6.5        | 5.8       |  |
| Dietary intake, mean                              |                                     |               |             |            |           |  |
| Vitamin B <sub>6</sub> , mg/d <sup>d</sup>        | 1.7                                 | 3.1           | 8.4         | 23.3       | 69.1      |  |
| Vitamin B <sub>12</sub> , µg/d <sup>d</sup>       | 7.4                                 | 12.7          | 22.4        | 31.6       | 48.2      |  |
| Calcium, mg/d <sup>d</sup>                        | 885                                 | 1167          | 1321        | 1345       | 1469      |  |
| Vitamin D, µg/d <sup>d</sup>                      | 5.0                                 | 9.9           | 12.5        | 12.2       | 13.7      |  |
| Retinol, µg/d <sup>d</sup>                        | 557                                 | 1104          | 1520        | 1596       | 2068      |  |
| Protein, g/d <sup>d</sup>                         | 67.7                                | 73.0          | 73.9        | 73.0       | 73.3      |  |
| Caffeine, mg/d                                    | 266                                 | 231           | 215         | 217        | 200       |  |
| Alcohol, g/d                                      | 6.2                                 | 5.4           | 5.5         | 5.4        | 5.4       |  |
| Multivitamin supplements, %                       | 17.0                                | 72.7          | 83.6        | 77.0       | 74.5      |  |
| Vitamin B <sub>6</sub> supplements, %             | 2.1                                 | 0.9           | 11.9        | 25.4       | 45.7      |  |
| Vitamin B complex, %                              | 0                                   | 0             | 11.9        | 27.8       | 36.9      |  |
| Vitamin B <sub>12</sub> supplements, %            | 2.3                                 | 3.2           | 9.0         | 14.6       | 24.7      |  |
| Difficulty climbing stairs or walking 1 block, %  | 6.2                                 | 5.7           | 6.2         | 6.5        | 6.6       |  |
| ≥2 Falls last year                                | 7.1                                 | 8.1           | 8.4         | 9.1        | 9.2       |  |
| Self-rated general health status not excellent, % | 10.1                                | 10.7          | 10.8        | 11.2       | 11.1      |  |
| Cancer, %   | 15.7                                | 17.2          | 17.8        | 18.2       | 17.6      |  |
| Diabetes, %                                       | 9.4                                 | 9.7           | 9.5         | 10.2       | 9.5       |  |
| Cardiovascular disease, %                         | 12.2                                | 12.3          | 12.9        | 12.9       | 12.3      |  |
| Osteoporosis, %                                   | 21.5                                | 24.3          | 25.4        | 25.9       | 27.2      |  |
| Medication use, %                                 |                                     |               |             |            |           |  |
| Current postmenopausal hormone therapy            | 29.0                                | 35.6          | 39.5        | 37.3       | 37.6      |  |
| Thiazide-like diuretic                            | 13.2                                | 15.2          | 15.4        | 15.4       | 14.0      |  |
| Furosemide diuretic                               | 3.2                                 | 3.9           | 3.9         | 3.9        | 4.8       |  |
| Oral corticosteroids                              | 2.3                                 | 2.5           | 2.6         | 2.6        | 2.8       |  |

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); MET, metabolic equivalent.

<sup>c</sup> Metabolic equivalent hours per week from discretionary physical activity (eg, 12 MET hours per week is equivalent to 4 hours per week of walking or 1 hour per week of running).

<sup>a</sup> Values are means and percentages and were standardized to the age distribution in 2002.

<sup>b</sup> Number of women participating in the 2002 questionnaire cycle.

<sup>d</sup> Cumulative mean daily intake from foods and supplements adjusted for total energy intake.

### JAMA Network Open | Nutrition, Obesity, and Exercise

had an RR of 1.71 (95% Cl, 1.25-2.34) for hip fracture compared with those having a low intake of both vitamins. The corresponding RR in women with BMI at least 25 was 1.04 (95% Cl, 0.66-1.64).

We observed no significant interactions between total vitamin  $B_6$  or vitamin  $B_{12}$  intakes and age, indicating that the proportional hazards assumption was met. Similarly, there was no significant interaction between total vitamin  $B_6$  intake and physical activity for fracture risk. However, a significant interaction was found between total vitamin  $B_{12}$  intake and physical activity. There was a significant linear trend with increasing intake among those with a physical activity level below the median (RR, 1.02; 95% CI, 1.00-1.03 per 10-µg/d increase in total intake; P = .02) but not among those with a higher physical activity level (RR, 1.01; 95% CI, 0.99-1.03 per 10-µg/d increase in total intake; P = .51). Stratified results are summarized in eTable 1 in the Supplement.

In additional analyses of the data in Table 3, the following had little influence on the estimates: adjustment for BMI 4 years before the last follow-up and later weight change, difficulty climbing a flight of stairs or walking 1 block, difficulty with balance, falls in the past year, self-reported general

Table 2. Age and Age-Adjusted Characteristics of 61 445 Women in the Nurses' Health Study Across Categories of Total Vitamin B<sub>12</sub> Intake (Diet and Supplements) in 2002, Cumulative Mean<sup>a</sup>

|   | Vitamin B <sub>12</sub> Intake, µg/d |              |               |             |            |  |  |
|---|--------------------------------------|--------------|---------------|-------------|------------|--|--|
| Variable  | <5                                   | 5-9.9        | 10-19.9       | 20-29.9     | ≥30        |  |  |
| No. (%) of population <sup>b</sup>                | 4820 (7.8)                           | 19888 (32.4) | 21 940 (35.7) | 6144 (10.0) | 8653 (14.1 |  |  |
| Age, mean, y                                      | 66.5                                 | 68.3         | 68.6          | 67.7        | 66.9       |  |  |
| Height at baseline, mean, cm                      | 164                                  | 164          | 164           | 164         | 164        |  |  |
| Current BMI, mean                                 | 26.3                                 | 26.7         | 26.7          | 26.7        | 26.4       |  |  |
| Physical activity, MET, h/wk <sup>c</sup>         | 16.1                                 | 16.4         | 17.6          | 18.0        | 19.1       |  |  |
| Current smoker, %                                 | 9.8                                  | 8.3          | 7.8           | 6.9         | 5.8        |  |  |
| Dietary intake, mean                              |                                      |              |               |             |            |  |  |
| Vitamin B <sub>6</sub> , mg/d <sup>d</sup>        | 3.8                                  | 4.6          | 7.6           | 16.4        | 36.7       |  |  |
| Vitamin B <sub>12</sub> , µg/d <sup>d</sup>       | 4.0                                  | 7.5          | 13.8          | 24.1        | 57.1       |  |  |
| Calcium, mg/d <sup>d</sup>                        | 886                                  | 1061         | 1244          | 1344        | 1423       |  |  |
| Vitamin D, µg/d <sup>d</sup>                      | 4.6                                  | 7.7          | 11.5          | 12.8        | 13.4       |  |  |
| Retinol, µg/d <sup>d</sup>                        | 393                                  | 816          | 1378          | 1631        | 1882       |  |  |
| Protein, g/d <sup>d</sup>                         | 66.2                                 | 71.5         | 73.8          | 74.0        | 73.2       |  |  |
| Caffeine, mg/d                                    | 245                                  | 243          | 228           | 221         | 203        |  |  |
| Alcohol, g/d                                      | 6.3                                  | 5.6          | 5.5           | 5.5         | 4.2        |  |  |
| Multivitamin supplements, %                       | 16.8                                 | 51.4         | 82.8          | 85.1        | 77.9       |  |  |
| Vitamin B <sub>6</sub> supplements, %             | 3.0                                  | 2.9          | 5.1           | 10.5        | 32.7       |  |  |
| Vitamin B complex, %                              | 0.1                                  | 0.2          | 3.7           | 17.5        | 31.2       |  |  |
| Vitamin B <sub>12</sub> supplements, %            | 0.1                                  | 0.1          | 0.2           | 3.1         | 47.4       |  |  |
| Difficulty climbing stairs or walking 1 block, %  | 5.3                                  | 5.5          | 6.2           | 6.2         | 6.8        |  |  |
| ≥2 Falls last year                                | 6.5                                  | 7.9          | 8.4           | 8.8         | 8.9        |  |  |
| Self-rated general health status not excellent, % | 9.2                                  | 10.6         | 10.9          | 11.2        | 11.3       |  |  |
| Cancer, %   | 15.1                                 | 16.6         | 17.6          | 18.0        | 18.1       |  |  |
| Diabetes, %                                       | 7.8                                  | 9.6          | 9.9           | 9.7         | 9.8        |  |  |
| Cardiovascular disease, %                         | 12.0                                 | 12.6         | 12.0          | 12.4        | 13.9       |  |  |
| Osteoporosis, %                                   | 21.6                                 | 23.3         | 25.7          | 24.1        | 26.0       |  |  |
| Medication use, %                                 |                                      |              |               |             |            |  |  |
| Current postmenopausal hormone therapy            | 30.9                                 | 33.6         | 36.9          | 35.6        | 38.6       |  |  |
| Thiazide-like diuretic                            | 12.9                                 | 14.4         | 15.6          | 15.3        | 14.7       |  |  |
| Furosemide diuretic                               | 3.3                                  | 3.6          | 4.1           | 3.9         | 4.5        |  |  |
| Oral corticosteroids                              | 2.5                                  | 2.2          | 2.6           | 2.8         | 2.7        |  |  |

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); MET, metabolic equivalent.

<sup>c</sup> Metabolic equivalent hours per week from discretionary physical activity (eg, 12 MET hours per week is equivalent to 4 hours per week of walking or 1 hour per week of running).

<sup>a</sup> Values are means and percentages and were standardized to the age distribution in 2002.

<sup>b</sup> Number of women participating in the 2002 questionnaire cycle.

<sup>d</sup> Cumulative mean daily intake from foods and supplements adjusted for total energy intake.

### JAMA Network Open | Nutrition, Obesity, and Exercise

health status, and pernicious anemia (eTable 2 in the Supplement). Adjustment for total folate intake had only a small influence on the associations between vitamin  $B_6$ , vitamin  $B_{12}$ , and hip fracture (eTable 3 in the Supplement).

In sensitivity analyses censoring participants at age 80 years, the association for total vitamin  $B_6$  intake was marginally stronger, whereas the results for total vitamin  $B_{12}$  intake were similar to the findings of the main analyses. The association for combined intakes of vitamins  $B_6$  and  $B_{12}$  as analyzed in Table 4 was also strengthened, with an RR of 1.74 (95% CI, 1.30-2.32) for women with a high intake of both vitamins.

In analyses conducted using current intakes of total vitamins  $B_6$  and  $B_{12}$ , a similar pattern was seen. However, it was somewhat weaker compared with the analysis using cumulative average intakes (eTable 4 and eTable 5 in the Supplement).

# Table 3. Relative Risk of Hip Fracture According to Intake of Total Vitamins B<sub>6</sub> and B<sub>12</sub> and From Supplements Only Among Women With 2304 Hip Fractures, the Nurses' Health Study, 1984-2014, Cumulative Mean

|   |       | Crude Incidence<br>per 10 000 | RR (95% CI)                          |                             |  |
|---|-------|-------------------------------|--------------------------------------|-----------------------------|--|
| Variable  | Cases | Person-Years                  | Age and Questionnaire Cycle Adjusted | Fully Adjusted <sup>a</sup> |  |
| Total vitamin B <sub>6</sub> , diet and supplements, mg/d |       |                               |                                      |                             |  |
| <2  | 315   | 9.8                           | 1 [Reference]                        | 1 [Reference]               |  |
| 2-4.9   | 1242  | 15.1                          | 1.06 (0.94-1.21)                     | 1.11 (0.95-1.29)            |  |
| 5-14.9  | 353   | 17.4                          | 1.13 (0.97-1.33)                     | 1.17 (0.97-1.41)            |  |
| 15-34.9   | 200   | 17.3                          | 1.07 (0.89-1.29)                     | 1.10 (0.89-1.35)            |  |
| ≥35   | 194   | 16.1                          | 1.22 (1.01-1.46)                     | 1.29 (1.04-1.59)            |  |
| P value for linear trend                                  | NA    | NA                            | .04                                  | .06                         |  |
| RR per 10-mg/d increase                                   | NA    | NA                            | 1.02 (1.00-1.04)                     | 1.02 (1.00-1.04)            |  |
| /itamin B <sub>6</sub> , supplements only, mg/d           |       |                               |                                      |                             |  |
| 0   | 123   | 5.2                           | 1 [Reference]                        | 1 [Reference]               |  |
| <2  | 1177  | 16.2                          | 1.37 (1.12-1.67)                     | 1.37 (1.12-1.69)            |  |
| 2-4.9   | 424   | 14.4                          | 1.37 (1.11-1.69)                     | 1.31 (1.04-1.65)            |  |
| 5-24.9  | 353   | 19.7                          | 1.50 (1.20-1.86)                     | 1.44 (1.14-1.82)            |  |
| ≥25   | 227   | 15.1                          | 1.42 (1.13-1.78)                     | 1.41 (1.10-1.80)            |  |
| P value for linear trend                                  | NA    | NA                            | .06                                  | .09                         |  |
| RR per 10-mg/d increase                                   | NA    | NA                            | 1.02 (1.00-1.04)                     | 1.02 (1.00-1.04)            |  |
| otal vitamin $B_{12}$ , diet and supplements, µg/d        |       |                               |                                      |                             |  |
| <5  | 162   | 9.8                           | 1 [Reference]                        | 1 [Reference]               |  |
| 5-9.9   | 687   | 12.1                          | 1.00 (0.84-1.19)                     | 1.01 (0.83-1.24)            |  |
| 10-19.9   | 888   | 15.9                          | 1.12 (0.95-1.33)                     | 1.09 (0.87-1.36)            |  |
| 20-29.9   | 230   | 17.3                          | 1.21 (0.99-1.49)                     | 1.21 (0.94-1.56)            |  |
| ≥30   | 337   | 21.4                          | 1.27 (1.04-1.54)                     | 1.25 (0.98-1.58)            |  |
| P value for linear trend                                  | NA    | NA                            | .004                                 | .02                         |  |
| RR per 10-µg/d increase                                   | NA    | NA                            | 1.02 (1.01-1.03)                     | 1.01 (1.00-1.03)            |  |
| /itamin $B_{12}$ , supplements only, µg/d                 |       |                               |                                      |                             |  |
| 0   | 161   | 8.1                           | 1 [Reference]                        | 1 [Reference]               |  |
| <5  | 969   | 13.2                          | 1.08 (0.91-1.28)                     | 1.06 (0.89-1.26)            |  |
| 5-9.9   | 486   | 15.8                          | 1.15 (0.96-1.38)                     | 1.10 (0.89-1.35)            |  |
| 10-24.9   | 369   | 18.9                          | 1.20 (0.99-1.46)                     | 1.16 (0.94-1.44)            |  |
| ≥25   | 319   | 21.0                          | 1.31 (1.07-1.59)                     | 1.26 (1.01-1.56)            |  |
| P value for linear trend                                  | NA    | NA                            | .03                                  | .09                         |  |
| RR per 10-µg/d increase                                   | NA    | NA                            | 1.01 (1.00-1.03)                     | 1.01 (1.00-1.02)            |  |

Abbreviations: NA, not applicable; RR, relative risk.

<sup>a</sup> Adjusted for age; questionnaire cycle; height; body mass index; physical activity; smoking status; dietary intakes of calcium, vitamin D, retinol, protein, caffeine, and alcohol; cancer; diabetes; cardiovascular disease; osteoporosis; postmenopausal hormone therapy; and use of thiazide diuretics, furosemide diuretics, and oral corticosteroids. In addition, vitamin B<sub>12</sub> from supplements is adjusted for vitamin B<sub>12</sub> from foods, and vitamin B<sub>6</sub> from supplements is adjusted for vitamin B<sub>6</sub> from foods.

# Discussion

We found that high intakes of vitamins  $B_6$  and  $B_{12}$  were associated with increased hip fracture risk among postmenopausal women in the Nurses' Health Study. The risk was highest in women with a combined high intake of both vitamins, exhibiting an almost 50% increased risk of hip fracture compared with women with a low intake of both vitamins. High intakes were due to use of supplements. These findings add to previous studies suggesting that vitamin supplements should be used cautiously because adverse effects can occur.

### **Other Studies**

Our findings are in line with the results of a secondary analysis of combined data from 2 Norwegian double-blind RCTs with an identical intervention (6837 participants) in which an unexpected increased risk of hip fracture was found in those treated with high doses of vitamin  $B_6$  during an extended follow-up.<sup>15</sup> Both RCTs had a 2 × 2 factorial design: the 4 groups were given (1) folic acid (0.8 mg) plus vitamin  $B_{12}$  (0.4 mg) and vitamin  $B_6$  (40 mg), (2) folic acid (0.8 mg) plus vitamin  $B_{12}$  (0.4 mg), or (4) placebo. Risk of hip fracture was highest in the first group (hazard ratio, 1.49; 95% CI, 1.05-2.11 compared with placebo).

We are not aware of other RCTs studying fractures that have supplemented with vitamin  $B_6$  alone, but several trials<sup>14</sup> have combined vitamins  $B_6$  and  $B_{12}$ . As summarized in eTable 6 in the Supplement, the results from the RCTs are divergent, as are the doses used and fracture type studied, making it difficult to draw firm conclusions. In the Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS),<sup>21</sup> there was no significant effect of the intervention (50 mg/d of vitamin  $B_6$  and 1 mg/d of vitamin  $B_{12}$  plus 2.5 mg/d of folic acid) on nonvertebral fractures (RR, 1.08; 95% CI, 0.88-1.34). A statistical interaction with baseline plasma  $B_6$  concentration was observed; when excluding women in the lower quartile of baseline vitamin  $B_6$ , there was a significantly increased risk of nonvertebral fractures (RR, 1.39; 95% CI, 1.01-1.91). The Heart Outcomes Prevention Evaluation (HOPE) 2 trial<sup>22</sup> intervened with 50 mg/d of vitamin  $B_6$ , 1 mg/d of vitamin  $B_{12}$ , and 2.5 mg/d of folic acid. There was a nonsignificant hazard ratio of 1.07 (95% CI, 0.85-1.33) for nonvertebral fractures. The Vitamins to Prevent Stroke (VITATOPS) trial<sup>23</sup> gave a lower dose of vitamin  $B_6$  (25 mg/d) in addition to 0.5 mg/d of vitamin  $B_{12}$  plus 2.0 mg/d of folic acid. The authors reported no significant effect on any osteoporotic fracture (n = 145) (hazard ratio, 0.86; 95% CI, 0.62-1.18) or hip fracture (n = 70) (hazard ratio, 0.94; 95% CI, 0.59-1.50).

Table 4. Relative Risk of Hip Fracture According to Combined Cumulative Mean Total Intakes of Vitamins B<sub>6</sub> and B<sub>12</sub> Among Women With 2304 Hip Fractures, the Nurses' Health Study, 1984-2014

| Variable <sup>a</sup>                            | Cases | Crude Incidence per<br>10 000 Person-Years | Age and Questionnaire<br>Cycle-Adjusted RR (95% CI) | Fully Adjusted<br>RR (95% CI) <sup>b</sup> |
|--|-------|--|---|--|
| Low B <sub>6</sub> and low B <sub>12</sub>       | 263   | 9.5  | 1 [Reference]                                       | 1 [Reference]                              |
| Medium B <sub>6</sub> and low B <sub>12</sub>    | 564   | 12.8                                       | 1.02 (0.88-1.19)                                    | 1.11 (0.94-1.31)                           |
| High B <sub>6</sub> and low B <sub>12</sub>      | 22    | 11.2                                       | 1.19 (0.77-1.85)                                    | 1.27 (0.82-1.98)                           |
| Low B <sub>6</sub> and medium B <sub>12</sub>    | 42    | 10.7                                       | 1.24 (0.89-1.74)                                    | 1.12 (0.79-1.59)                           |
| Medium B <sub>6</sub> and medium B <sub>12</sub> | 812   | 16.5                                       | 1.14 (0.99-1.32)                                    | 1.18 (0.98-1.42)                           |
| High $B_6$ and medium $B_{12}$                   | 34    | 12.4                                       | 1.10 (0.77-1.58)                                    | 1.17 (0.80-1.72)                           |
| Low B <sub>6</sub> and high B <sub>12</sub>      | 10    | 15.6                                       | 1.30 (0.69-2.45)                                    | 1.17 (0.62-2.22)                           |
| Medium B <sub>6</sub> and high B <sub>12</sub>   | 419   | 19.8                                       | 1.25 (1.06-1.47)                                    | 1.31 (1.07-1.60)                           |
| High $B_6$ and high $B_{12}$                     | 138   | 18.9                                       | 1.33 (1.08-1.65)                                    | 1.47 (1.15-1.89)                           |

Abbreviation: RR, relative risk.

 $^{\rm a}$  Cutoffs for vitamin B<sub>6</sub> are 2 and 35 mg/d; cutoffs for vitamin B<sub>12</sub> are 10 and 20  $\mu$ g/d.

<sup>b</sup> Adjusted for age; questionnaire cycle; height; body mass index; physical activity; smoking status; dietary intakes of calcium, vitamin D, retinol, protein, caffeine, and alcohol; cancer; diabetes; cardiovascular disease; osteoporosis; postmenopausal hormone therapy; and use of thiazide diuretics, furosemide diuretics, and oral corticosteroids.

### **Possible Mechanisms**

A possible biological explanation for the findings in the present study is not clear. The magnitude of intakes of vitamins  $B_6$  and  $B_{12}$  associated with an increased risk of hip fracture in our study far exceeded the recommended dietary allowances (RDAs) (1.3-1.7 mg/d for vitamin  $B_6$  and 2.4 µg/d for vitamin  $B_{12}$ ).<sup>15</sup>

Possible adverse effects of high-dose vitamin  $B_6$  supplementation have previously been suggested.<sup>24,25</sup> High doses ( $\geq$ 500 mg/d) might increase the risk of falling because neurological symptoms, including ataxia, neuropathy, and decreased muscle tone, have been reported, and milder neurological symptoms have been observed at doses of approximately 100 mg/d as adverse effects.<sup>26</sup> Preliminary work suggested that high vitamin  $B_6$  concentrations might accelerate bone loss by counteracting the modulating influence of estrogens on steroid receptors.<sup>27</sup> A recent paradox theory proposes that large doses of pyridoxine, the inactive form of vitamin  $B_6$  included in supplements and found in foods, inhibits the active form pyridoxal phosphate.<sup>28</sup>

We do not have an explanation for the mechanism by which vitamin  $B_{12}$  may contribute to increased fracture risk. However, as summarized in Table 4 and in eTable 5 in the Supplement, a high

# Table 5. Relative Risk of Hip Fracture According to Cumulative Mean Intake of B Vitamins Stratified by Body Mass Index Among Women With 2257 Hip Fractures, the Nurses' Health Study, 1984-2014<sup>a</sup>

| Variable                             | Cases | Fully Adjusted RR (95% CI) <sup>b</sup> |
|--------------------------------------|-------|---|
| BMI <25 (1409 Hip Fractures)         |       |   |
| Total vitamin B <sub>6</sub> , mg/d  |       |   |
| <2                                   | 196   | 1 [Reference]                           |
| 2-4.9                                | 736   | 1.08 (0.89-1.31)                        |
| 5-14.9                               | 216   | 1.14 (0.90-1.44)                        |
| 15-34.9                              | 125   | 1.10 (0.84-1.43)                        |
| ≥35                                  | 136   | 1.48 (1.13-1.93)                        |
| P value for linear trend             | NA    | .006                                    |
| RR per 10-mg/d increase              | NA    | 1.03 (1.01-1.06)                        |
| Total vitamin B <sub>12</sub> , μg/d |       |   |
| <5                                   | 99    | 1 [Reference]                           |
| 5-9.9                                | 421   | 1.22 (0.94-1.58)                        |
| 10-19.9                              | 547   | 1.31 (0.99-1.74)                        |
| 20-29.9                              | 119   | 1.24 (0.89-1.72)                        |
| ≥30                                  | 223   | 1.51 (1.11-2.04)                        |
| P value for linear trend             | NA    | .03                                     |
| RR per 10-mg/d increase              | NA    | 1.02 (1.00-1.03)                        |
| BMI ≥25 (842 Hip Fractures)          |       |   |
| Total vitamin B <sub>6</sub> , mg/d  |       |   |
| <2                                   | 112   | 1 [Reference]                           |
| 2-4.9                                | 476   | 1.10 (0.86-1.41)                        |
| 5-14.9                               | 130   | 1.19 (0.88-1.62)                        |
| 15-34.9                              | 69    | 1.06 (0.75-1.50)                        |
| ≥35                                  | 55    | 1.01 (0.70-1.47)                        |
| P value for linear trend             | NA    | .93                                     |
| RR per 10-mg/d increase              | NA    | 1.00 (0.96-1.04)                        |
| Total vitamin B <sub>12</sub> , µg/d |       |   |
| <5                                   | 60    | 1 [Reference]                           |
| 5-9.9                                | 253   | 0.76 (0.54-1.07)                        |
| 10-19.9                              | 321   | 0.78 (0.54-1.13)                        |
| 20-29.9                              | 104   | 1.08 (0.71-1.64)                        |
| ≥30                                  | 104   | 0.81 (0.53-1.23)                        |
| P value for linear trend             | NA    | .62                                     |
| RR per 10-mg/d increase              | NA    | 1.01 (0.98-1.03)                        |

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); NA, not applicable; RR, relative risk.

- <sup>a</sup> Some individuals had missing BMI and were excluded from the analyses.
- <sup>b</sup> Adjusted for age; questionnaire cycle; height; BMI (as continuous variable); physical activity; smoking status; dietary intakes of calcium, vitamin D, retinol, protein, caffeine, and alcohol; cancer; diabetes; cardiovascular disease; osteoporosis; postmenopausal hormone therapy; and use of thiazide diuretics, furosemide diuretics, and oral corticosteroids.

intake of vitamin  $B_{12}$  and a low intake of vitamin  $B_6$  were not associated with increased risk, which is in agreement with a meta-analysis<sup>14</sup> of RCTs giving vitamin  $B_{12}$  and/or folic acid alone (without vitamin  $B_6$ ).

A possible explanation for the interaction between total vitamin  $B_6$  intake and BMI is not clear. At low BMI, fracture risk was higher, and a larger number of incident hip fractures thus occurred, yielding higher statistical power. We speculate that the possible mechanism of excessive vitamin  $B_6$  exposure increasing fall risk through neurological symptoms could particularly aggravate fracture risk in women with low BMI, who are more prone to fracturing their hip when experiencing a fall. However, adjustment for falls had little influence on the estimates, and the association between falls and fracture risk was not altered by adjustment for vitamins  $B_6$  and  $B_{12}$  intakes. It also could be that the possible interaction between vitamin  $B_6$  and the steroid receptor might be most influential in lean women, who have a reduced capacity for production of adipose-derived estrogens.<sup>29</sup>

## **Strengths and Limitations**

Our study has strengths and limitations. We were able to follow up a large cohort of women with repeated detailed assessments of diet, supplement use, and other possible confounding factors. However, we cannot exclude the possibility that individuals started taking supplements due to ill health. In addition, all information on vitamin intake and confounders was collected by questionnaires, with their inherent limitations. Although residual confounding could be present, our results were not substantially influenced by adjustment for indicators of frailty or disease or a long list of other possible confounders. Another limitation was the self-report of hip fractures. However, in sensitivity analyses censoring participants at age 80 years (thus omitting the oldest, in whom underreporting of fracture could be an issue), the association for total vitamin B<sub>6</sub> intake was marginally stronger. An additional limitation is that the findings may be applicable only to women of white race/ethnicity.

The results for supplemental vitamin  $B_6$  are puzzling because all categories above the reference category have similar increases in risk. Also, intakes of different supplements are correlated, making it challenging to disentangle specific associations. Nevertheless, our results were adjusted for intake of calcium, vitamin D, and retinol, and the differences between the model adjusted for age and questionnaire cycle and the fully adjusted models were modest.

We did not control for multiple hypothesis testing. However, our analyses were based on the RCT results, in which the highest fracture risk was found in those treated with high doses of both vitamins.<sup>15</sup> A low proportion of the women were in the low-intake category of both vitamins. Yet, compared with the group with a medium intake of both vitamin  $B_6$  (2 to <35 mg/d) and vitamin  $B_{12}$  (10 to <20 µg/d), the risk was still significantly increased in those with a high intake of both vitamins (RR, 1.25; 95% CI, 1.03-1.51).

### Implications

The RDAs are established to meet the nutritional requirements of almost the entire population. Despite that, use of high-dose vitamin supplementation far exceeding the RDAs is common, often without any definite indication and in the absence of clear evidence of benefit.

Our results are in line with several reports suggesting that unexpected adverse effects can occur with high-dose vitamin supplementation. For example, high-dose beta-carotene supplementation increased the risk of lung cancer in smokers,<sup>3</sup> and high-dose vitamin E supplementation may increase all-cause mortality.<sup>4</sup> Higher risk of fracture was reported in 2 RCTs<sup>5,6</sup> after treatment with annual megadoses of vitamin D, and possible adverse effects of homocysteine-lowering treatment with B vitamins have been observed,<sup>9,11</sup> including a potentially increased risk of cancer.<sup>12</sup> Although we acknowledge the limitations of our cohort design, the findings herein add to the body of literature that suggests caution should be used in vitamin supplementation when there is no apparent deficiency.

### Conclusions

In this large prospective cohort study of postmenopausal women in the Nurses' Health Study, we found that a combined high intake of vitamins  $B_6$  and  $B_{12}$  was associated with an increased risk of hip fracture. These findings add to previous studies suggesting that vitamin supplements should be used cautiously because adverse effects can occur.

### **ARTICLE INFORMATION**

Accepted for Publication: March 22, 2019.

Published: May 10, 2019. doi:10.1001/jamanetworkopen.2019.3591

**Open Access:** This is an open access article distributed under the terms of the CC-BY License. © 2019 Meyer HE et al. *JAMA Network Open*.

Corresponding Author: Haakon E. Meyer, MD, PhD, Department of Community Medicine and Global Health, University of Oslo, PO Box 1130 Blindern, O318 Oslo, Norway (h.e.meyer@medisin.uio.no).

Author Affiliations: Department of Community Medicine and Global Health, University of Oslo, Oslo, Norway (Meyer); Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts (Meyer, Willett, Fung); Division of Mental and Physical Health, Norwegian Institute of Public Health, Oslo, Norway (Meyer, Holvik); Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (Willett, Feskanich); Department of Nutrition, Simmons University, Boston, Massachusetts (Fung).

Author Contributions: Drs Meyer and Feskanich had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Meyer, Willett, Feskanich.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Meyer, Holvik.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Meyer, Willett, Feskanich.

Obtained funding: Willett.

Administrative, technical, or material support: Willett.

Conflict of Interest Disclosures: None reported.

Funding/Support: This work was supported by grants CA186107 and AG030521 from the National Institutes of Health.

**Role of the Funder/Sponsor:** The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

#### REFERENCES

1. Kantor ED, Rehm CD, Du M, White E, Giovannucci EL. Trends in dietary supplement use among US adults from 1999-2012. *JAMA*. 2016;316(14):1464-1474.

2. Kim HJ, Giovannucci E, Rosner B, Willett WC, Cho E. Longitudinal and secular trends in dietary supplement use: Nurses' Health Study and Health Professionals Follow-Up Study, 1986-2006. *J Acad Nutr Diet*. 2014;114(3): 436-443.

3. Druesne-Pecollo N, Latino-Martel P, Norat T, et al. Beta-carotene supplementation and cancer risk: a systematic review and metaanalysis of randomized controlled trials. *Int J Cancer*. 2010;127(1):172-184.

**4**. Miller ER III, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. *Ann Intern Med*. 2005;142(1):37-46.

5. Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. *JAMA*. 2010;303(18):1815-1822.

**6**. Smith H, Anderson F, Raphael H, Maslin P, Crozier S, Cooper C. Effect of annual intramuscular vitamin D on fracture risk in elderly men and women: a population-based, randomized, double-blind, placebo-controlled trial. *Rheumatology (Oxford)*. 2007;46(12):1852-1857.

7. Zhang C, Wang ZY, Qin YY, Yu FF, Zhou YH. Association between B vitamins supplementation and risk of cardiovascular outcomes: a cumulative meta-analysis of randomized controlled trials. *PLoS One*. 2014;9(9): e107060.

**8**. Myung SK, Ju W, Cho B, et al; Korean Meta-Analysis Study Group. Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. *BMJ*. 2013;346:f10.

**9**. Clarke R, Halsey J, Lewington S, et al; B-Vitamin Treatment Trialists' Collaboration. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37 485 individuals. *Arch Intern Med*. 2010;170(18):1622-1631.

**10**. Vollset SE, Clarke R, Lewington S, et al; B-Vitamin Treatment Trialists' Collaboration. Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals. *Lancet*. 2013;381(9871):1029-1036.

11. Løland KH, Bleie O, Blix AJ, et al. Effect of homocysteine-lowering B vitamin treatment on angiographic progression of coronary artery disease: a Western Norway B Vitamin Intervention Trial (WENBIT) substudy. *Am J Cardiol.* 2010;105(11):1577-1584.

**12**. van Wijngaarden JP, Swart KM, Enneman AW, et al. Effect of daily vitamin B-12 and folic acid supplementation on fracture incidence in elderly individuals with an elevated plasma homocysteine concentration: B-PROOF, a randomized controlled trial. *Am J Clin Nutr.* 2014;100(6):1578-1586.

**13**. Herrmann M, Peter Schmidt J, Umanskaya N, et al. The role of hyperhomocysteinemia as well as folate, vitamin B<sub>6</sub> and B<sub>12</sub> deficiencies in osteoporosis: a systematic review. *Clin Chem Lab Med*. 2007;45(12):1621-1632.

**14**. Garcia Lopez M, Baron JA, Omsland TK, Søgaard AJ, Meyer HE. Homocysteine-lowering treatment and the risk of fracture: secondary analysis of a randomized controlled trial and an updated meta-analysis. *JBMR Plus*. 2018;2 (5):295-303.

**15**. Garcia Lopez M, Bønaa KH, Ebbing M, et al. B vitamins and hip fracture: secondary analyses and extended follow-up of two large randomized controlled trials. *J Bone Miner Res*. 2017;32(10):1981-1989.

**16**. Colditz GA, Martin P, Stampfer MJ, et al. Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. *Am J Epidemiol*. 1986;123(5):894-900.

17. Willett WC. Nutritional Epidemiology. 3rd ed. New York, NY: Oxford University Press; 2013.

**18**. Yuan C, Spiegelman D, Rimm EB, et al. Validity of a dietary questionnaire assessed by comparison with multiple weighed dietary records or 24-hour recalls. *Am J Epidemiol*. 2017;185(7):570-584.

**19**. Zhang SM, Willett WC, Selhub J, et al. Plasma folate, vitamin B<sub>6</sub>, vitamin B<sub>12</sub>, homocysteine, and risk of breast cancer. *J Natl Cancer Inst.* 2003;95(5):373-380.

**20**. Ainsworth BE, Haskell WL, Leon AS, et al. Compendium of physical activities: classification of energy costs of human physical activities. *Med Sci Sports Exerc*. 1993;25(1):71-80.

**21.** Stone KL, Lui LY, Christen WG, et al. Effect of combination folic acid, vitamin  $B_{6}$ , and vitamin  $B_{12}$  supplementation on fracture risk in women: a randomized, controlled trial. *J Bone Miner Res.* 2017;32(12): 2331-2338.

22. Sawka AM, Ray JG, Yi Q, Josse RG, Lonn E. Randomized clinical trial of homocysteine level-lowering therapy and fractures. *Arch Intern Med*. 2007;167(19):2136-2139.

**23**. Gommans J, Yi Q, Eikelboom JW, Hankey GJ, Chen C, Rodgers H; VITATOPS Trial Study Group. The effect of homocysteine-lowering with B-vitamins on osteoporotic fractures in patients with cerebrovascular disease: substudy of VITATOPS, a randomised placebo-controlled trial. *BMC Geriatr.* 2013;13:88.

24. Collier J. Vitamin B-6: food or medicine? the rules—and the politics—are different. BMJ. 1998;317(7151):92-93.

**25**. Still time for rational debate about vitamin B<sub>6</sub>. *Lancet*. 1998;351(9115):1523.

26. Dalton K, Dalton MJ. Characteristics of pyridoxine overdose neuropathy syndrome. *Acta Neurol Scand*. 1987; 76(1):8-11.

**27**. Allgood VE, Cidlowski JA. Vitamin B<sub>6</sub> modulates transcriptional activation by multiple members of the steroid hormone receptor superfamily. *J Biol Chem.* 1992;267(6):3819-3824.

**28**. Vrolijk MF, Opperhuizen A, Jansen EHJM, Hageman GJ, Bast A, Haenen GRMM. The vitamin B<sub>6</sub> paradox: supplementation with high concentrations of pyridoxine leads to decreased vitamin B<sub>6</sub> function. *Toxicol In Vitro*. 2017;44:206-212.

29. Shapses SA, Sukumar D. Bone metabolism in obesity and weight loss. Annu Rev Nutr. 2012;32:287-309.

### SUPPLEMENT.

eFigure. Flow of Inclusion for the Analyses of Vitamins B<sub>6</sub> and B<sub>12</sub> and Hip Fracture in the Nurse's Health Study Starting in 1984

eTable 1. Relative Risk (RR) of Hip Fracture According to Intake of Vitamin B<sub>12</sub> Among Women, the Nurses' Health Study (1986-2014)

**eTable 2.** Relative Risk (RR) of Hip Fracture According to Cumulative Average Intake of Vitamins B<sub>6</sub> and B<sub>12</sub> Among Women, the Nurses' Health Study

**eTable 3.** Relative Risk (RR) of Hip Fracture According to Cumulative Average Intake of Vitamin  $B_{6}$ , Vitamin  $B_{12}$ , and Folate Among Women, the Nurses' Health Study (1986-2014) (2,304 Hip Fractures)

**eTable 4.** Relative Risk (RR) of Hip Fracture According to Intakes of Vitamins B<sub>6</sub> and B<sub>12</sub> Among Women, the

Nurses' Health Study (1986-2014) (2,812 Hip Fractures), Current Intake

**eTable 5.** Relative Risk (RR) of Hip Fracture According to Current Intake of Vitamins B<sub>6</sub> and B<sub>12</sub> Among Women, the Nurses' Health Study (1986-2014) (2,812 Hip Fractures)

**eTable 6.** Randomized Controlled Trials Intervening With Both Vitamin  $B_6$  and  $B_{12}$  and Reporting on the Risk of Fracture

eReferences.